Human Metabolome Technologies, Inc. (TYO:6090)

Market Cap	3.93B -4.7%
Revenue (ttm)	1.43B +2.4%
Net Income	206.00M -22.3%
EPS	35.85 -20.0%
Shares Out	5.63M
PE Ratio	19.50
Forward PE	n/a
Dividend	18.00 (2.58%)
Ex-Dividend Date	Jun 29, 2026

Volume	2,700
Average Volume	8,290
Open	699.00
Previous Close	699.00
Day's Range	698.00 - 704.00
52-Week Range	631.00 - 869.00
Beta	-0.09
RSI	48.45
Earnings Date	May 8, 2026

About TYO:6090

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, prec...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2003
• Employees: 62
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6090

Financial Performance

In fiscal year 2025, TYO:6090's revenue was 1.46 billion, an increase of 8.18% compared to the previous year's 1.35 billion. Earnings were 256.00 million, an increase of 5.35%.